Lunatic Fringe (LFNG) Human shRNA Plasmid Kit (Locus ID 3955)

CAT#: TR315472

LFNG - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector

Specifications

Product Data

• Locus ID: 3955
• Synonyms: SCDO3
• Vector: pRS
• Format: Retroviral plasmids
• Kit Components: LFNG - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 3955). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
• RefSeq: NM_001040167, NM_001040168, NM_001166355, NM_002304, BC014851, BM854210
• Summary: This gene is a member of the glycosyltransferase 31 gene family. Members of this gene family, which also includes the MFNG (GeneID: 4242) and RFNG (GeneID: 5986) genes, encode evolutionarily conserved glycosyltransferases that act in the Notch signaling pathway to define boundaries during embryonic development. While their genomic structure is distinct from other glycosyltransferases, these proteins have a fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity that leads to elongation of O-linked fucose residues on Notch, which alters Notch signaling. The protein encoded by this gene is predicted to be a single-pass type II Golgi membrane protein but it may also be secreted and proteolytically processed like the related proteins in mouse and Drosophila (PMID: 9187150). Mutations in this gene have been associated with autosomal recessive spondylocostal dysostosis 3. [provided by RefSeq, May 2018]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).